Beautycounter founder Gregg Renfrew will return to the company as CEO after selling the business in 2021 to the Carlyle Group, announces Counter Brands, LLC, a division of the private equity firm. In a 19 January release, the Santa Monica-based firm notes Renfrew, who will replace interim CEO and board director Mindy Mackenzie, will assume the role on 1 February. Counter Brands reported it was seeking a permanent replacement last summer. (Also see "L’Oreal Bets On Biotech; Beautycounter Launches CEO Search; NIVEA ‘Skin Out Loud’; Cosmetics News" - HBW Insight, 7 June, 2023.)
Beautycounter Founder Returns As CEO; Inter Parfum’s FY2023 Results; Cosmetics News
Gregg Renfrew will start as CEO at the company she founded on 1 February. Separately, International Flavors & Fragrances taps J. Erik Fyrwald to succeed Frank Clyburn as CEO, Inter Parfums reports fiscal 2023 full-year results, Yellow Wood Partners acquires Chapstick, and more.
More from Leadership
• By
A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.
• By
The General Services Administration’s updated list of “assets identified for accelerated disposition” does not include any buildings at the agency’s headquarters in White Oak, MD after its original list of “non-core” government properties for disposal had more than half the buildings on campus.
• By
Round up of the latest appointments: PAGB names vice presidents; Activ'Inside gets first US head; EMA elects management board chair.
• By
Stakeholders are pleading for newly confirmed FDA Commissioner Martin Makary to stand up for the agency's high scientific standards and staff as he begins his term.
More from HBW Insight
• By
A round-up of the latest industry moves in Europe: Pharma Deutschland elects board of new Brussels operation; MHRA's new CEO gets to work; Futura names non-executive director.
• By
“If this doesn’t get reauthorized, look at the number of the ingredients out there, the number of products, what would happen all those products out there for the consumer, on that shelf, in the drugstore or someplace?” says Rep. Bob Latta during House hearing.
• By
Energy and Commerce Health Subcommittee Democrats focus on criticizing HHS Secretary Kennedy’s RIF announcement, including 3,500 FDA jobs among cuts across HHS agencies. “If we reauthorize it, will it continue?” Texas representative Lizzie Fletcher asks of OMUFA.